SPRO - Spero Therapeutics GAAP EPS of -$0.23 beats by $0.11 revenue of $2.72M beats by $1.64M
2023-08-10 16:19:42 ET
- Spero Therapeutics press release ( NASDAQ: SPRO ): Q2 GAAP EPS of -$0.23 beats by $0.11 .
- Revenue of $2.72M (+36.7% Y/Y) beats by $1.64M .
- Total revenues for the second quarter of 2023 were $2.7 million, compared with revenues of $2.0 million in the second quarter of 2022. Revenue was approximately $0.7 million higher year over year due to revenue recognition associated with the GSK transaction.
For further details see:
Spero Therapeutics GAAP EPS of -$0.23 beats by $0.11, revenue of $2.72M beats by $1.64M